Celebrex: Targeted Relief for Osteoarthritis and Rheumatoid Arthritis
Celebrex
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.00 (0%) | 🛒 Add to cart |
| 90 | $0.70 | $73.50 $63.00 (14%) | 🛒 Add to cart |
| 120 | $0.63 | $98.00 $76.00 (22%) | 🛒 Add to cart |
| 180 | $0.58 | $147.00 $104.00 (29%) | 🛒 Add to cart |
| 270 | $0.54 | $220.50 $147.00 (33%) | 🛒 Add to cart |
| 360 | $0.53
Best per pill | $294.00 $189.00 (36%) | 🛒 Add to cart |
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.00 (0%) | 🛒 Add to cart |
| 60 | $0.98 | $84.00 $59.00 (30%) | 🛒 Add to cart |
| 90 | $0.84 | $126.00 $76.00 (40%) | 🛒 Add to cart |
| 120 | $0.78 | $168.00 $93.00 (45%) | 🛒 Add to cart |
| 180 | $0.72 | $252.00 $129.00 (49%) | 🛒 Add to cart |
| 270 | $0.66 | $378.00 $179.00 (53%) | 🛒 Add to cart |
| 360 | $0.64
Best per pill | $504.00 $232.00 (54%) | 🛒 Add to cart |
Synonyms
| |||
Celebrex (celecoxib) is a prescription nonsteroidal anti-inflammatory drug (NSAID) classified as a COX-2 selective inhibitor. It is specifically engineered to provide effective anti-inflammatory and analgesic action while minimizing the gastrointestinal complications often associated with traditional NSAIDs. This medication is indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain in adults. Its mechanism of action involves the selective inhibition of the cyclooxygenase-2 (COX-2) enzyme, which plays a key role in inflammation and pain mediation.
Features
- Active Pharmaceutical Ingredient: Celecoxib
- Pharmacologic Class: COX-2 selective nonsteroidal anti-inflammatory drug (NSAID)
- Available Strengths: 50 mg, 100 mg, 200 mg, and 400 mg capsules
- Administration: Oral
- Formulation: Hard gelatin capsules
- Prescription Status: Rx-only medication
Benefits
- Provides significant reduction in joint pain and stiffness associated with osteoarthritis and rheumatoid arthritis.
- Demonstrates a lower incidence of gastrointestinal ulceration and bleeding compared to non-selective NSAIDs.
- Offers once-daily or twice-daily dosing convenience for improved patient adherence.
- Effectively manages acute pain and primary dysmenorrhea.
- Improves physical function and overall quality of life in chronic inflammatory conditions.
- Allows for long-term management of chronic pain with a monitored safety profile.
Common use
Celebrex is predominantly prescribed for the management of chronic inflammatory conditions. Its primary indications include the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis in adults. It is also approved for the management of acute pain, such as that following surgical or dental procedures, and for the treatment of primary dysmenorrhea. In pediatric patients, it is used for juvenile rheumatoid arthritis in children aged 2 years and older. Off-label uses may include the management of other pain syndromes, though such use requires careful risk-benefit assessment by a healthcare provider.
Dosage and direction
For osteoarthritis, the recommended dose is 200 mg per day, administered as a single dose or as 100 mg twice daily. For rheumatoid arthritis, the dose is 100 mg to 200 mg twice daily. For the management of acute pain or primary dysmenorrhea, the initial dose is 400 mg, followed by an additional 200 mg dose if needed on the first day, with subsequent doses of 200 mg twice daily as required. For ankylosing spondylitis, the recommended dose is 200 mg daily in single or divided doses; if no effect is observed after 6 weeks, a trial of 400 mg daily may be considered. The maximum recommended daily dose is 400 mg for most indications. Celebrex should be taken with a full glass of water and may be administered with or without food. Dosage adjustment is recommended for patients with hepatic impairment.
Precautions
Patients should be advised that Celebrex, like other NSAIDs, may cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular disease or risk factors for cardiovascular disease. Celebrex is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs, including Celebrex, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. Celebrex may lead to the onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of cardiovascular events. Patients should be monitored closely for signs and symptoms of heart failure, edema, and hypertension. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.
Contraindications
Celebrex is contraindicated in patients with known hypersensitivity to celecoxib. It should not be used in patients who have demonstrated allergic-type reactions to sulfonamides. Celebrex is contraindicated in patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. Celebrex is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. It is also contraindicated in patients with a history of gastrointestinal bleeding or active peptic ulcer disease.
Possible side effect
Common adverse reactions (occurring in >2% of patients) include headache, dyspepsia, upper respiratory tract infection, diarrhea, sinusitis, abdominal pain, and nausea. Serious side effects may include cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity (elevations of ALT and/or AST), hypertension, heart failure, renal toxicity, anaphylactic reactions, serious skin reactions, and hematologic toxicity (anemia). Patients should be monitored for signs of these serious adverse events. Postmarketing reports have included acute renal failure, interstitial nephritis, and exacerbation of inflammatory bowel disease.
Drug interaction
Celebrex metabolism is primarily mediated via cytochrome P450 2C9. Co-administration with drugs that inhibit CYP2C9 (such as fluconazole) may increase celecoxib plasma concentrations. Conversely, inducers of CYP2C9 may decrease celecoxib concentrations. Concomitant use with aspirin is not generally recommended because of the potential for increased GI toxicity. Celebrex can reduce the antiplatelet effect of low-dose aspirin. Concomitant administration with warfarin may lead to increased prothrombin time and risk of bleeding. Celebrex may diminish the antihypertensive effect of ACE inhibitors and angiotensin II receptor blockers. Concurrent use with lithium may result in increased lithium plasma levels. NSAIDs may increase methotrexate toxicity. Concomitant use with other NSAIDs or corticosteroids may increase the risk of GI adverse events.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in dosing is important for maintaining therapeutic effect, particularly in chronic conditions.
Overdose
Symptoms of overdose may include lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding, hypertension, acute renal failure, respiratory depression, coma, and anaphylaxis. There is no specific antidote for celecoxib overdose. Management should be supportive and symptomatic. Gastric lavage or administration of activated charcoal may be considered if performed soon after ingestion. Hemodialysis is not expected to be effective in removing celecoxib due to high protein binding. Forced diuresis, alkalization of urine, or hemoperfusion may not be useful due to high protein binding.
Storage
Celebrex capsules should be stored at room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication must be kept in its original container, tightly closed, and protected from moisture and light. It should be kept out of reach of children and pets. Unused or expired medication should be disposed of properly according to local guidelines, not flushed down the toilet or poured into drains.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the current prescribing information but may not be exhaustive. Individual patient responses to medication can vary.
Reviews
Clinical studies and post-marketing surveillance have demonstrated Celebrex to be effective in reducing pain and improving function in patients with osteoarthritis and rheumatoid arthritis. In numerous randomized controlled trials, Celebrex showed significant improvement in pain scores and patient global assessment compared to placebo. Many patients report substantial improvement in daily activities and quality of life. However, some patients may experience inadequate pain relief or adverse effects. The cardiovascular and gastrointestinal risk profile, while improved compared to non-selective NSAIDs, remains a consideration in treatment decisions. Patient satisfaction often correlates with effective pain control and tolerability. Adherence to prescribed dosing and regular monitoring are critical for optimal outcomes.